These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11486312)

  • 21. Progress in hematopoietic stem cell transplantation in multiple myeloma.
    Gahrton G
    Curr Opin Hematol; 2005 Nov; 12(6):463-70. PubMed ID: 16217163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma.
    Björkstrand B
    Semin Hematol; 2001 Jul; 38(3):219-25. PubMed ID: 11486309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.
    Ma SY; Lie AK; Au WY; Chim CS; Kwong YL; Liang R
    Hong Kong Med J; 2004 Apr; 10(2):77-83. PubMed ID: 15075426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation.
    Gahrton G; Svensson H; Björkstrand B; Apperley J; Carlson K; Cavo M; Ferrant A; Fouillard L; Gratecos N; Gratwohl A; Guilhot F; Lambertenghi Deliliers G; Ljungman P; Masszi T; Milligan DW; Powles RL; Reiffers J; Samson JD; Stoppa AM; Vernant JP; Volin L; Wallvik J
    Bone Marrow Transplant; 1999 Oct; 24(7):741-5. PubMed ID: 10516677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
    Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma.
    Majolino I; Corradini P; Scimè R; Santoro A; Tarella C; Cavallaro AM; Palumbo A; Indovina A; Caracciolo D; Boccadoro M; Marcenò R; Pileri A
    Bone Marrow Transplant; 1998 Sep; 22(5):449-55. PubMed ID: 9733268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic stem cell transplantation for multiple myeloma.
    Bensinger W
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):891-902. PubMed ID: 25212888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of allografting with autografting for newly diagnosed myeloma.
    Bruno B; Rotta M; Patriarca F; Mordini N; Allione B; Carnevale-Schianca F; Giaccone L; Sorasio R; Omedè P; Baldi I; Bringhen S; Massaia M; Aglietta M; Levis A; Gallamini A; Fanin R; Palumbo A; Storb R; Ciccone G; Boccadoro M
    N Engl J Med; 2007 Mar; 356(11):1110-20. PubMed ID: 17360989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic haemopoietic stem cell transplantation for multiple myeloma or plasma cell leukaemia using fractionated total body radiation and high-dose melphalan conditioning.
    Russell N; Bessell E; Stainer C; Haynes A; Das-Gupta E; Byrne J
    Acta Oncol; 2000; 39(7):837-41. PubMed ID: 11145442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
    Randall K; Kaparou M; Xenou E; Paneesha S; Kishore B; Kanellopoulos A; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
    Eur J Haematol; 2017 Oct; 99(4):300-305. PubMed ID: 28632322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
    Zeiser R; Finke J
    Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
    Donato ML; Siegel DS; Vesole DH; McKiernan P; Nyirenda T; Pecora AL; Baker M; Goldberg SL; Mato A; Goy A; Rowley SD
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1211-6. PubMed ID: 24792872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.
    Ramasamy K; Mahmood S; Lim Z; Corderoy S; Devereux S; Mufti GJ; Pagliuca A; Schey S
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):242-5. PubMed ID: 21575930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on the treatment of multiple myeloma.
    Kyle RA
    Oncologist; 2001; 6(2):119-24. PubMed ID: 11306723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Stem cell transplantation in multiple myeloma].
    Fukuda S; Sunami K; Sezaki T
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1407-14. PubMed ID: 10500527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome.
    Nivison-Smith I; Dodds AJ; Doocey R; Ganly P; Gibson J; Ma DD; Simpson JM; Szer J; Bradstock KF
    Leuk Lymphoma; 2011 Sep; 52(9):1727-35. PubMed ID: 21864043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
    Costa LJ; Kumar S; Dispenzieri A; Hayman SE; Buadi FK; Dingli D; Litzow MR; Gertz MA; Lacy MQ
    Leuk Lymphoma; 2009 May; 50(5):781-7. PubMed ID: 19330657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma.
    Cavo M; Benni M; Gozzetti A; Tura S
    Baillieres Clin Haematol; 1995 Dec; 8(4):795-813. PubMed ID: 8845573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.